JP2733259B2 - Porous microcellulose particles - Google Patents

Porous microcellulose particles

Info

Publication number
JP2733259B2
JP2733259B2 JP63233656A JP23365688A JP2733259B2 JP 2733259 B2 JP2733259 B2 JP 2733259B2 JP 63233656 A JP63233656 A JP 63233656A JP 23365688 A JP23365688 A JP 23365688A JP 2733259 B2 JP2733259 B2 JP 2733259B2
Authority
JP
Japan
Prior art keywords
cellulose
particles
porous
sample
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP63233656A
Other languages
Japanese (ja)
Other versions
JPH0284401A (en
Inventor
義仁 柳沼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Original Assignee
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Kogyo KK filed Critical Asahi Kasei Kogyo KK
Priority to JP63233656A priority Critical patent/JP2733259B2/en
Publication of JPH0284401A publication Critical patent/JPH0284401A/en
Application granted granted Critical
Publication of JP2733259B2 publication Critical patent/JP2733259B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241Containing particulates characterized by their shape and/or structure
    • A61K8/0279Porous; Hollow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/412Microsized, i.e. having sizes between 0.1 and 100 microns

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は多孔性微小セルロース粒子に関するものであ
り、さらに詳しくは従来のものにはない大きな比表面積
と発達した細孔構造を有し、かつ結晶形がI型であるこ
とを特徴とする多孔性微小セルロース粒子に関するもの
である。本発明物質は食品、医薬品の吸着担体、圧縮成
形助剤、流動性改良剤、化粧品の添加剤などに利用され
る。
DETAILED DESCRIPTION OF THE INVENTION (Industrial application field) The present invention relates to porous microcellulose particles, and more specifically, has a large specific surface area and a developed pore structure which are not available in the prior art, and The present invention relates to porous microcellulose particles having a crystalline form of I type. The substance of the present invention is used as an adsorption carrier for foods and pharmaceuticals, a compression molding aid, a fluidity improver, an additive for cosmetics, and the like.

(従来の技術) 多孔性のセルロース粒子は従来、ゲル濾過剤、セルロ
ース性イオン交換体の原料、アフィニティークロマトグ
ラフィー用担体、高分子担体、化粧品添加剤等として種
々の分野で使用されている。その製造方法としては例え
ばビスコースを凝固再生浴中に粒状で落下させて凝固再
生を行わせることにより16〜170メッシュの多孔性再生
セルロース粒子を得る方法(特開昭48−60753号)や、
アンモニア性水酸化銅溶液にセルロースを溶解し、乳化
剤を含むベンゼン中に滴下してセルロース溶液を分散
後、再生浴にこれを投入してセルロース小球を得る方法
(特公昭52−11237号)、三酢酸セルロースの粒状粒子
をケン化することにより多孔性セルロース球状粒子を得
る方法(特公昭63−12099号)などが開示されている。
しかしそれらはクロマトグラフィー用担体として用いら
れるため製品は通常湿潤した状態であり、乾燥すると収
縮を起こして充分な細孔容積を維持することができな
い。
(Prior Art) Porous cellulose particles have been conventionally used in various fields as gel filtration agents, raw materials for cellulosic ion exchangers, carriers for affinity chromatography, polymer carriers, cosmetic additives and the like. Examples of the production method include a method of obtaining porous regenerated cellulose particles of 16 to 170 mesh by dropping viscose in a granular form in a coagulation / regeneration bath and performing coagulation / regeneration (JP-A-48-60753).
A method in which cellulose is dissolved in an ammoniacal copper hydroxide solution and dropped into benzene containing an emulsifier to disperse the cellulose solution, and then poured into a regenerating bath to obtain cellulose globules (Japanese Patent Publication No. 52-11237), A method for obtaining porous cellulose spherical particles by saponifying cellulose triacetate particles (Japanese Patent Publication No. 63-12099) is disclosed.
However, since they are used as chromatographic supports, the products are usually in a wet state, and when dried, shrinkage occurs and a sufficient pore volume cannot be maintained.

またそれらはセルロースもしくはセルロース誘導体の
溶解・再生操作を行っているがために、その結晶形はII
型となっている。
In addition, since they carry out dissolving and regenerating operations of cellulose or cellulose derivatives, their crystal forms are II
It is a type.

乾燥状態の多孔性セルロース粒子としては特公昭57−
45254号に、水不混和性液体中のビスコース懸濁液を加
熱することにより固化し、次いで酸分解して球状セルロ
ース粒子を得る方法が示されており、その中に「約30%
以下の気孔率を有する粒子は寸法安定性であり、乾燥で
きる」との記載があるが、使用目的に適応しないため具
体的な既述は示されていない。また、特開昭63−90501
号には、セルロースザンテートと水溶性高分子化合物の
アルカリ水溶液の混合物の微粒子状分散液を凝固・中和
後、該水溶性高分子を除去することにより多孔性のセル
ロース粒子を得る方法が示されているが比表面積に関す
る記載は全くない。これらとても溶解・再生操作を行っ
ているから製品の結晶形はやはりII型である。
As a dried porous cellulose particle,
No. 45254 discloses a method of solidifying a viscose suspension in a water-immiscible liquid by heating, followed by acid decomposition to obtain spherical cellulose particles.
Particles having the following porosity are dimensionally stable and can be dried. " Also, JP-A-63-90501
No. 3 discloses a method for obtaining porous cellulose particles by coagulating and neutralizing a fine particle dispersion of a mixture of cellulose xanthate and an aqueous alkali solution of a water-soluble polymer compound, and then removing the water-soluble polymer. However, there is no description about the specific surface area. Since these melting and regenerating operations are performed, the crystal form of the product is still type II.

セルロースの結晶形はI型、II型、III型、IV型など
が知られておりその中で特にI型は「天然セルロー
ス」、II型は「再生セルロース」と呼ばれている。天然
セルロースは古来、植物繊維として食用に供しており、
又、現在では液状食品の分散安定剤や医薬品の賦形剤と
して広く使用されており、再生セルロースは服飾材料で
あるレーヨン糸やキュプラ糸、前出のクロマトグラフィ
ー用担体としての球状粒子として使用されている。I型
とII型では使用分野が異っており、結晶形の違いは使用
目的により留意すべき問題である。
The crystalline forms of cellulose are known as type I, type II, type III, type IV, etc. Among them, type I is particularly called "natural cellulose" and type II is called "regenerated cellulose". Natural cellulose has been used for food as plant fiber since ancient times,
At present, regenerated cellulose is widely used as a dispersion stabilizer for liquid foods and as an excipient for pharmaceuticals, and regenerated cellulose is used as rayon or cupra threads as clothing materials, and as spherical particles as a carrier for chromatography described above. ing. The fields of use are different between type I and type II, and the difference in crystal form is a problem to be noted depending on the purpose of use.

比表面積の大なるセルロース粉末は有機溶媒置換法や
臨界点乾燥法を用いることにより調整し得ることが知ら
れている。(臼田誠人、紙パ技協誌、36 (4)、423
−433(1982))しかしそれらはおおよそ300Å以下の細
孔を有するにとどまり、それ以上の大きな細孔を有する
ことはなく、またその細孔容積も充分なものとはいえな
い。
It is known that cellulose powder having a large specific surface area can be adjusted by using an organic solvent replacement method or a critical point drying method. (Masato Usuda, Journal of Paper and Technology Association, 36 (4), 423
-433 (1982)) However, they have pores of about 300 ° or less, do not have pores larger than that, and their pore volume is not sufficient.

(本発明が解決しようとする問題点) 本発明者は従来のものとは異なる、発達した細孔構造
を有し、かつ、充分な気孔容積を有し、さらには乾燥状
態で大なる比表面積を有する多孔質の天然セルロース微
小粒子を得るために鋭意努力を重ねた結果、本発明に到
達したものである。本発明の目的は新規な多孔性の微小
セルロース粒子を提供することにある。
(Problems to be solved by the present invention) The present inventor has a developed pore structure different from conventional ones, has a sufficient pore volume, and has a large specific surface area in a dry state. As a result of intensive efforts to obtain porous natural cellulose microparticles having the following, the present invention has been achieved. An object of the present invention is to provide a novel porous microcellulose particle.

従来知られている多孔性セルロース粒子は前述の通
り、いずれもセルロースもしくはセルロース誘導体の溶
解・再生操作を行っているがためにその結晶形はII型と
なっており、また乾燥状態で発達した細孔構造(直径の
大きな細孔と充分な細孔容積)と大きな比表面積を合わ
せもつものはなかった。
As described above, all of the conventionally known porous cellulose particles have been subjected to dissolving and regenerating operations of cellulose or a cellulose derivative, so that the crystal form is II type, and the fine particles developed in a dry state. None had a combination of pore structure (large diameter pores and sufficient pore volume) and large specific surface area.

(問題を解決するための手段) 本発明は、結晶形がI型であり、比表面積が20m2/g以
上でかつ直径0.01μm以上の細孔容積が0.3cm3/g以上の
多孔構造を有し、そして平均粒径が大きくとも100μm
であることを特徴とする多孔性セルロース微小粒子に関
するものである。
(Means for Solving the Problems) The present invention relates to a porous structure having a crystalline form of type I, a specific surface area of 20 m 2 / g or more, and a pore volume of 0.01 μm or more and a pore volume of 0.3 cm 3 / g or more. Has an average particle size of at most 100 μm
The present invention relates to porous cellulose fine particles characterized by the following.

以下、本発明について詳細に説明する。 Hereinafter, the present invention will be described in detail.

本発明による多孔性セルロース微小粒子の結晶形はI
型であり、ラミー、コットンリンター、木材パルプ等の
天然セルロースと同じ結晶構造を有している。さらに本
発明による多孔性セルロース微小粒子は長径と短径の比
が比較的1に近い球状を呈している場合が多く、その表
面は1μm以下の微小な孔を無数に有するような状態
か、もしくはその多孔質面と棒状のセルロース粒子が混
在するような状態となっている。多孔性は表面のみなら
ず内部にも及んでおり、直径0.01μm以上の細孔の容積
は0.3cm3/g以上でかつ比表面積が20m2/g以上であるとい
う微細細孔構造を有している。
The crystalline form of the porous cellulose microparticles according to the present invention is I
It has the same crystal structure as natural cellulose such as ramie, cotton linter and wood pulp. Furthermore, the porous cellulose microparticles according to the present invention often have a spherical shape in which the ratio of the major axis to the minor axis is relatively close to 1, and the surface thereof has a countless number of minute pores of 1 μm or less, or The porous surface and rod-like cellulose particles are mixed. The porosity extends not only to the surface but also to the inside.It has a fine pore structure in which the volume of pores with a diameter of 0.01 μm or more is 0.3 cm 3 / g or more and the specific surface area is 20 m 2 / g or more. ing.

これら微細細孔構造を規定する3つの条件のいずれが
欠けても本発明の目的とする効果を発揮し得ない。一般
に細孔の直径が大きな場合、例えば0.1μm以上である
とすると細孔容積は大となりやすく、又、細孔直径が小
さな場合は比表面積が大となりやすい。しかし、特に溶
解・再生操作を取り得ない天然セルロース粒子の場合、
この3つの物性を制御することが困難であったが、本発
明による多孔性セルロース粒子はそれらを兼ね備えてお
り、そのために医薬品の吸着担体や粉体の圧縮成形助剤
として極めて優れた性質を発揮し得るものである。
If any of these three conditions that define the fine pore structure is missing, the effects intended by the present invention cannot be achieved. Generally, when the pore diameter is large, for example, 0.1 μm or more, the pore volume tends to be large, and when the pore diameter is small, the specific surface area tends to be large. However, especially in the case of natural cellulose particles which cannot be dissolved and regenerated,
Although it was difficult to control these three physical properties, the porous cellulose particles according to the present invention have both of them, and therefore exhibit extremely excellent properties as an adsorption carrier for pharmaceuticals and a compression molding aid for powders. Can be done.

また本発明による多孔性セルロース粒子は平均粒径が
100μm以下である。これは、一般に平均粒径が100μm
以上の粉体は他の粉体との混合性が悪く、粉としての欠
点を感じるようになるためであり、例えば、医薬品製剤
の混合粉体の流動性改良剤として本発明品を用いた場
合、平均粒径が大きいと他の粉との分離が生じ、その機
能を充分に発揮し得なくなる。
The porous cellulose particles according to the present invention have an average particle size.
100 μm or less. This generally means that the average particle size is 100 μm
This is because the above powder has poor mixing properties with other powders and causes a disadvantage as a powder.For example, when the product of the present invention is used as a fluidity improver for a mixed powder of a pharmaceutical preparation. On the other hand, if the average particle size is large, separation from other powders occurs, and the function cannot be sufficiently exhibited.

本発明の多孔性セルロース微小粒子は例えば以下の方
法により製造されるが、これらの方法に限定されるもの
ではない。
The porous cellulose microparticles of the present invention are produced, for example, by the following methods, but are not limited to these methods.

本発明の多孔性セルロース微小粒子は有機溶媒に分散
させた微粒子状天然セルロースをスプレードライ法によ
り造粒、乾燥することで得ることができる。
The porous cellulose fine particles of the present invention can be obtained by granulating and drying particulate fine cellulose dispersed in an organic solvent by a spray drying method.

セルロース微粒子の有機溶媒スラリーは種々の方法で
調整することができる。例えば、天然セルロース原料を
化学的処理(酸加水分解等)および、もしくは機械的処
理(粉砕、摩砕等)により微粒子状のセルロース粒子と
し、この時分散媒となっている水を有機溶媒で置換し、
さらに固形分濃度を調節することでスプレードライに供
するスラリーを調整することができる。この際、要は有
機溶媒中に微粒子状セルロースが分散している状態にし
てやればよいわけだから、有機溶媒置換後のスラリーに
対し摩砕処理を加えることで目的を達成してもよい。む
しろ有機溶媒置換操作(有機溶媒分散、濾過の繰り返
し)の作業性はその方が良好である。分散微粒子の大き
さは10μm以下好ましくは1μm以下であることが本発
明の中間原料として適当である。天然セルロース原料と
してはセルロースI型の結晶形を有するラミー、コット
ンリンター、木材パルプなどが用いられ、また有機溶媒
としてはアセトン、メタノール、エタノール、イソプロ
ピルアルコール、n−ヘキサン、n−ペンタン、シクロ
ヘキサン、ペンゼン等の1種もしくは2種以上が使用さ
れる。(2種以上の使用の際は、段階的な逐次置換とな
る。) スプレードライはスラリーの分散媒が有機溶媒である
から防爆を考慮したクローズトシステムの、例えば窒素
ガス循環型のスプレードライヤーを使用して行う必要が
ある。
The organic solvent slurry of the cellulose fine particles can be adjusted by various methods. For example, natural cellulose raw material is finely divided into cellulose particles by chemical treatment (acid hydrolysis, etc.) and / or mechanical treatment (pulverization, milling, etc.), and at this time, water serving as a dispersion medium is replaced with an organic solvent. And
Further, the slurry to be spray-dried can be adjusted by adjusting the solid content concentration. At this time, since it is essential that the particulate cellulose is dispersed in the organic solvent, the purpose may be achieved by subjecting the slurry after the replacement with the organic solvent to a grinding treatment. Rather, the workability of the organic solvent replacement operation (repetition of organic solvent dispersion and filtration) is better. It is suitable that the size of the dispersed fine particles is 10 μm or less, preferably 1 μm or less as an intermediate material in the present invention. As a natural cellulose raw material, ramie, cotton linter, wood pulp or the like having a cellulose I type crystal form is used, and as an organic solvent, acetone, methanol, ethanol, isopropyl alcohol, n-hexane, n-pentane, cyclohexane, pentane One or more of these are used. (In the case of using two or more types, it becomes a stepwise sequential replacement.) Spray drying is a closed system considering explosion proof, such as a nitrogen gas circulation type spray dryer because the dispersion medium of the slurry is an organic solvent. Must be done using

(発明の効果) 本発明によって得られる多孔性セルロース微小粒子は
今までに知られていない細孔構造、細孔容積及び比表面
積を有する天然セルロース粒子であり、造粒されている
がために粉体としての自流動性に優れている。他の粉体
と混合するような場合、特に本発明品の粒度分布がシャ
ープである場合、その混合粉体の流動性が極めて向上
し、例えば医薬品製剤の処方に組み入れ直接粉末圧縮法
にて錠剤を製すると錠剤の重量バラツキが著しく低減さ
れる。また発達した細孔構造と充分な比表面積を有する
がために、直接粉末圧縮法における添加剤として必要な
性質である圧縮成形性に優れ、特に成形性の劣る処方系
に配合した場合においてその効果は顕著となる。さら
に、アスピリンのような昇華性を有する主薬と本発明品
を物理混合すると主薬が細孔に吸着され、結局主薬の溶
出速度が著しく早くなることから、医薬品製剤の溶出性
改善剤として利用することも可能である。
(Effect of the Invention) The porous cellulose fine particles obtained by the present invention are natural cellulose particles having a pore structure, a pore volume, and a specific surface area which have not been known so far. Excellent self-fluidity as a body. When mixed with other powders, particularly when the particle size distribution of the product of the present invention is sharp, the fluidity of the mixed powder is extremely improved, for example, tablets incorporated by direct powder compression in a pharmaceutical formulation In this case, the weight variation of the tablet is significantly reduced. In addition, because it has a developed pore structure and a sufficient specific surface area, it has excellent compression moldability, which is a property required as an additive in the direct powder compression method. Becomes noticeable. Furthermore, when a main drug having a sublimability such as aspirin and the present invention are physically mixed, the main drug is adsorbed to the pores, and the dissolution rate of the main drug is significantly increased. Is also possible.

本発明品は天然セルロースであるから食用として自由
に供し得ることができ、また化学的に不活性であること
から医薬品製剤や酵素製剤等の製剤の安定化にも寄与す
る。
Since the product of the present invention is natural cellulose, it can be used freely as food, and because it is chemically inert, it contributes to the stabilization of pharmaceuticals and enzyme preparations.

また、多孔性のセルロース粒子は液体クロマトグラフ
ィー用のカラム充填剤として利用され中でもI型の結晶
構造を有するセルロース粒子はアミノ酸の光学異性体の
光学分割に使用し得ることが知られているが、本発明の
多孔性セルロース微粒子は比表面積が大であることか
ら、そのようなカラム充填剤として優秀な性能を有す
る。
Further, it is known that porous cellulose particles are used as a column filler for liquid chromatography, and among them, cellulose particles having a type I crystal structure can be used for optical resolution of optical isomers of amino acids. Since the porous cellulose fine particles of the present invention have a large specific surface area, they have excellent performance as such a column packing.

その他に本発明品は化粧品の配合剤としても使用し得
る。例えば固形のファンデーションに配合すると多孔性
であること、又、粒子が大きすぎないことから、のび特
性が良くなり、またセルロースの特性上(吸湿性等)他
の化粧品配合成分や皮脂あるいは汗の含みが良好である
ため化粧くずれしにくく、かつ軽い使用感が得られるよ
うになる。またクリーム、乳液等の乳化型の化粧料に配
合すると乳化性が安定し、使用時ののびが軽く、使用後
はさっぱり感、かつしっとり感の優れたものとなる。
In addition, the product of the present invention can be used as a compounding agent for cosmetics. For example, when incorporated into a solid foundation, it is porous, and its particles are not too large, so that it has good spreadability, and because of the characteristics of cellulose (such as hygroscopicity), it contains other cosmetic ingredients and sebum or sweat. Is good, the makeup is hardly distorted, and a light feeling of use can be obtained. When incorporated into emulsified cosmetics such as creams and emulsions, the emulsifying properties are stable, the spread at the time of use is light, and after use the product has an excellent refreshing and moist feeling.

実施例に先立ち、製品粒子の物性評価法及び錠剤物性
の測定方法について説明する。
Prior to Examples, a method for evaluating physical properties of product particles and a method for measuring physical properties of tablets will be described.

<平均粒子系(μm)> 柳本製作所製ロータップ式篩振盪機によりJIS標準篩
(Z8801−1987)を用いて試料50gを30分間篩分し、累積
50重量%の粒度を平均粒子径とする。粒径が小さくて篩
分け法で平均粒径が求められない場合は顕微鏡法を用い
て測定した。顕微鏡法は試料粉末を水、エタノール、グ
リセリンの等重量混合溶液に適当量分散させ、これを光
学顕微鏡にて写真撮影し、その写真に写っている個々の
粒子について粒子径を測定し、その平均をもって平均粒
径とするものである。粒子径の測定は任意な一方向の2
平行線で挟まれた距離として求め、検体数は200個とし
た。
<Average particle system (μm)> A 50 g sample was sieved for 30 minutes using a JIS standard sieve (Z8801-1987) using a Yanagimoto low tap sieve shaker, and accumulated.
The particle size of 50% by weight is defined as the average particle size. When the average particle size was not determined by the sieving method due to the small particle size, the measurement was performed using a microscope. Microscopy involves dispersing an appropriate amount of a sample powder in a mixed solution of equal weights of water, ethanol and glycerin, taking a photograph with an optical microscope, measuring the particle size of each particle in the photograph, and averaging the average particle size. Is defined as the average particle size. Measurement of particle size can be made in any one direction.
The number of samples was determined as the distance between the parallel lines, and the number of samples was 200.

<細孔直径(μm)及び細孔容積(cm3/g)> 島津製作所(株)ポアサイザー9300を用い、水銀ポロ
シメトリーにより細孔分布を求め、細孔容積は粒子内水
銀侵入体積をもって表わした。
<Pore diameter (μm) and pore volume (cm 3 / g)> The pore distribution was determined by mercury porosimetry using Shimadzu Corporation's Pore Sizer 9300, and the pore volume was expressed as the mercury penetration volume in the particles. .

<比表面積(m2/g)> 吸着物質として窒素を用い、BET法にて測定した。<Specific surface area (m 2 / g)> It was measured by the BET method using nitrogen as an adsorbing substance.

<結晶形> X線ディフラクトメーターによりX線回折を行い、そ
のディフラクトブラムより判定した。
<Crystal Form> X-ray diffraction was performed with an X-ray diffractometer, and the determination was made based on the diffractogram.

<安息角(゜)> 筒井理化学器械(株)製安息角測定器(ターンテーブ
ル型)により円錐堆積法を利用して測定した。繰り返し
数は3でその平均値をとる。
<Angle of Repose (゜)> The angle of repose was measured using a cone angle deposition method with a repose angle measuring instrument (turntable type) manufactured by Tsutsui Physical and Chemical Instruments. The number of repetitions is 3, and the average value is taken.

<錠剤哽度(kg)> プロイント産業(株)製シュロインガー哽度計で錠剤
の径方向に荷重を加え、破壊した時の荷重で表わす。繰
り返し数は10でその平均値をとる。
<Tablet strength (kg)> A load is applied in the radial direction of a tablet with a Schleinger gauge measured by Proint Sangyo Co., Ltd., and is expressed as the load when broken. The number of repetitions is 10 and the average is taken.

<錠剤重量バラツキ(%)> 錠剤10錠をそれぞれ精秤し、変動係数を求める。<Tablet weight variation (%)> Ten tablets are precisely weighed, and the coefficient of variation is determined.

(実施例) 実施例1 市販DPパルプを切断し、7%塩酸水溶液中で105℃で2
0分間加水分解して得られた酸不溶解残渣を中和、洗
浄、濾過・脱水したウェットケーク(水分含量50%)3.
0kgを10ニーダーにて約1時間混練、摩砕した。この
摩砕ウェットケークの水分をイソプロピルアルコール
(以下、IPAと略)で置換し、最終的に固形分(セルロ
ース分)濃度が5.5重量%、水分が0.4重量%、IPAが94.
1重量%となるようにスラリーを調整した。このとき微
粒子状セルロースはそのほとんどが1μm以下に摩砕さ
れた状態であった。
(Example) Example 1 Commercially available DP pulp was cut and placed in a 7% hydrochloric acid aqueous solution at 105 ° C for 2 hours.
Wet cake (50% moisture content) obtained by neutralizing, washing, filtering and dehydrating the acid-insoluble residue obtained by hydrolysis for 0 minutes 3.
0 kg was kneaded and milled in a 10 kneader for about 1 hour. The water in the milled wet cake was replaced with isopropyl alcohol (hereinafter abbreviated as IPA), and finally the solid content (cellulose content) concentration was 5.5% by weight, the water content was 0.4% by weight, and the IPA was 94.
The slurry was adjusted to 1% by weight. At this time, most of the particulate cellulose was in a state of being ground to 1 μm or less.

このスラリーを窒素循環型のスプレードライヤーを用
い噴霧乾燥を行ったところ、極めて球形に近い粒子から
成る粉体を得ることができた。この粉体の45μm以上の
粗粒分をカットし(JIS Z 8801 45μmによる)その篩
過留分を試料Aとした。試料Aの基礎物性を第1表に示
す。
When this slurry was spray-dried using a nitrogen circulation type spray drier, it was possible to obtain a powder composed of extremely spherical particles. A coarse particle of 45 μm or more of this powder was cut (according to JIS Z 8801 45 μm) and the sieved fraction was used as Sample A. Table 1 shows the basic physical properties of Sample A.

実施例2 実施例1と同様にして得られたウェットケークをIPA
に分散し、濾過・脱水、再分散を2回行い、さらに日本
精機製作所(株)製、ゴーリンホモジナイザー15M型を
用い、処理圧400kg/cm2で3回分散処理を行い、これを
実施例1と同様に噴霧乾燥した。乾燥前のスラリーは固
形分濃度が9.8重量%、水分が2.5重量%、IPAが87.7重
量%という組成であった。得られたサンプルは標準篩
(JIS Z 8801 250μm)を用いて250μm以上の粗粒分
をカットし、その250μm以下の球状試料を試料Bし
た。試料Bの基礎物性第1表に示す。
Example 2 The wet cake obtained in the same manner as in Example 1 was subjected to IPA
The mixture was subjected to filtration, dehydration and redispersion twice, and further subjected to a dispersion treatment three times at a processing pressure of 400 kg / cm 2 using a Gorin homogenizer 15M type manufactured by Nippon Seiki Seisakusho Co., Ltd. Spray-dried in the same manner as described above. The slurry before drying had a composition having a solid content of 9.8% by weight, a water content of 2.5% by weight, and an IPA of 87.7% by weight. The obtained sample was cut into coarse particles of 250 μm or more using a standard sieve (JIS Z 8801 250 μm), and the spherical sample of 250 μm or less was used as Sample B. The basic physical properties of Sample B are shown in Table 1.

比較例1 実施例1と同様にして得られたウェットケーク1kgを
アセトン2に分散し、濾過・脱水した。このアセトン
置換したウェットケークを五橋製作所製高速混合造粒機
NSK 250型に入れ、撹拌羽根の回転速度500rpmで1分間
解砕・造粒した。この710μm以下の留分(JIS Z 8801
710μmによる)を50℃で18時間乾燥して球状試料Cを
得た。試料Cの基礎物性を第1表に示す。
Comparative Example 1 1 kg of the wet cake obtained in the same manner as in Example 1 was dispersed in acetone 2, filtered and dehydrated. This acetone-replaced wet cake is a high-speed mixing granulator manufactured by Gohashi Seisakusho
The mixture was placed in an NSK 250 type and crushed and granulated for 1 minute at a rotation speed of a stirring blade of 500 rpm. This fraction of 710 μm or less (JIS Z 8801
(According to 710 μm) was dried at 50 ° C. for 18 hours to obtain a spherical sample C. Table 1 shows the basic physical properties of Sample C.

比較例2 市販微結晶セルロース「アビセルPH−101」「旭化成
工業(株)製)を試料Dとした。試料Dの基礎物性を第
1表に示す。
Comparative Example 2 Commercially available microcrystalline cellulose “AVICEL PH-101” (manufactured by Asahi Kasei Kogyo Co., Ltd.) was used as Sample D. The basic physical properties of Sample D are shown in Table 1.

第1表を見るとわかるように、微粒状セルロースのIP
Aスラリーの噴霧乾燥品である試料A及び試料Bは細孔
容積も比表面積も充分大きく、かつ、平均粒径が100μ
m以下というものであった。ちなみに試料Bの細孔容積
が試料Aのそれよりも大きいにもかかわらず比表面積が
小さいというのは細孔の大きさが違うためである。(試
料Aの細孔は試料Bのそれよりも小さい。)摩砕処理や
噴霧乾燥を行わずに調整したセルロース粒子である試料
Cは細孔容積は充分であったが比表面積が低く、又、既
存のセルロース粉末である試料Dは細孔容積、比表面積
ともに満足のいくものではない。
As can be seen from Table 1, the IP of finely divided cellulose
Samples A and B, which are spray-dried products of A slurry, have a sufficiently large pore volume and specific surface area, and an average particle size of 100 μm.
m or less. Incidentally, the reason that the specific surface area is small even though the pore volume of the sample B is larger than that of the sample A is because the pore size is different. (The pores of sample A are smaller than those of sample B.) Sample C, which is a cellulose particle prepared without milling or spray drying, has a sufficient pore volume but a low specific surface area. However, the existing cellulose powder, Sample D, is not satisfactory in both the pore volume and the specific surface area.

以上のように、実施例に示したような操作を行うこと
で今までにその存在が知られていなかった、結晶形がI
型であり、比表面積が20m2/g以上、直径0.01μm以上の
細孔の容積が0.3cm3/g以上でかつ平均径粒が100μm以
下であるという新規な多孔性セルロース微小粒子を得る
ことができた。
As described above, by performing the operation shown in the example, the crystal form of which the existence was not known until now was
To obtain novel porous cellulose microparticles having a specific surface area of 20 m 2 / g or more, a pore volume of 0.01 μm or more having a pore volume of 0.3 cm 3 / g or more and an average diameter of 100 μm or less. Was completed.

以下、使用例により本発明の効果を説明する。 Hereinafter, the effects of the present invention will be described with use examples.

使用例1 試料A.Bを各々90gと細川鉄工所(株)製バンタムミル
・AP−B型(使用スクリーン径0.5mmφ)で微粉砕した
局方フェナセチン(山本化学工業(株)製)60g、局方
コーンスターチ(日澱化学(株)製)30g、乳糖(DMV社
製、100メッシュ)120gをポリ袋中にて3分間混合した
後、局方ステアリン酸マグネシウム(太平化学産業
(株)製)を1.5g加え、更に30秒間混合したものを、菊
水製作所(株)製RT−S−9型ロータリー打錠機で8mm
φ、12Rの杵を用いて回転速度25rpm、成形圧1000kgf/cm
2で打錠成形し、重量200mgの錠剤を得た。その錠剤の物
性を第2表に示す。
Usage Example 1 90 g of sample AB and 60 g of phenacetin pharmacological agent (Yamamoto Kagaku Kogyo Co., Ltd.) pulverized finely with a bantam mill AP-B type (use screen diameter 0.5 mmφ) manufactured by Hosokawa Ironworks Co., Ltd. After mixing 30 g of Nisseki Chemical Co., Ltd. and 120 g of lactose (DMV, 100 mesh) in a plastic bag for 3 minutes, 1.5 g of magnesium stearate (Taipei Chemical Industry Co., Ltd.) was obtained. In addition, the mixture was further mixed for 30 seconds, and the mixture was mixed with an RT-S-9 type rotary tableting machine manufactured by Kikusui Seisakusho Co., Ltd.
φ, rotation speed 25rpm using a 12R punch, molding pressure 1000kgf / cm
The resulting mixture was compression-molded to obtain a tablet weighing 200 mg. Table 2 shows the physical properties of the tablets.

比較使用例1 試料C.Dを使用例1と同様にして打錠成形した。結果
を第2表に示す。
Comparative Use Example 1 A sample CD was tableted in the same manner as in Use Example 1. The results are shown in Table 2.

比較使用例2 市販微結晶セルロース「アビセルPH−301」(旭化成
工業(株)製)を試料Eとして使用例1と同様に打錠成
形した。結果を第2表に示す。
Comparative Use Example 2 A commercially available microcrystalline cellulose “Avicel PH-301” (manufactured by Asahi Kasei Kogyo Co., Ltd.) was tablet-formed as Sample E in the same manner as in Use Example 1. The results are shown in Table 2.

第2表を見ると試料A.Bの安息角が他に比べて低いこ
とがわかる。(ここで安息角は打錠に供した混合粉体に
対する測定値である。)安息角が低いということは打錠
してできた錠剤の重量バラツキも低いであろうと予想さ
れるわけだがやはり試料A.Bの重量バラツキも他に比べ
て低い。重量バラツキという値は粉の流動性というより
も打錠機の臼への充填性の良し悪しを示す値で直接粉末
圧縮法に対する粉の適応性はこの値をもって判断される
ものである。それは安息角が低くても重量バラツキが大
きい、ということが、例えば試料DとEの間の関係のよ
うに有りがちなことである また錠剤として大事な性質の1つである哽度において
も本発明品である試料A.Bは市販の直打用賦形剤である
試料D.Eよりも高い値をとっている。試料Cは各値とも
ほどほどの値をとっているが粒径が大きくため他の粉体
とのなじみが悪く、分離・偏析が問題となる。
Table 2 shows that the angle of repose of sample AB is lower than the others. (Here, the angle of repose is a measured value for the mixed powder used for tableting.) A low angle of repose is expected to mean that the weight variation of the tablets obtained by compression is also low, but the sample AB Is also lower than others. The value of the weight variation indicates the quality of the filling of the powder into the mill of the tableting machine rather than the fluidity of the powder, and the adaptability of the powder to the direct powder compression method is determined based on this value. It is common that the weight variation is large even if the angle of repose is low, for example, as in the relationship between samples D and E. Sample AB, which is an invention, has a higher value than sample DE, which is a commercially available excipient for direct hitting. Sample C has a moderate value for each value, but its large particle size makes it less compatible with other powders, and causes separation and segregation problems.

以上のように本発明による多孔性セルロース微小粒子
は医薬品製剤等の直接打錠用の圧縮成形助剤及び流動性
改良剤としての優秀な性質を有している。
As described above, the porous cellulose microparticles according to the present invention have excellent properties as compression molding aids and flow improvers for direct compression of pharmaceutical preparations and the like.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】結晶形がI型であり、比表面積が20m2/g以
上でかつ直径0.01μm以上の細孔の容積が0.3cm3/g以上
の多孔構造を有し、そして平均粒径が大きくとも100μ
mであることを特徴とする多孔性微小セルロース粒子
(1) a crystal form of type I, a porous structure having a specific surface area of at least 20 m 2 / g and a volume of pores having a diameter of 0.01 μm or more of 0.3 cm 3 / g or more, and an average particle size of Is at most 100μ
m, the porous microcellulose particles
JP63233656A 1988-09-20 1988-09-20 Porous microcellulose particles Expired - Lifetime JP2733259B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63233656A JP2733259B2 (en) 1988-09-20 1988-09-20 Porous microcellulose particles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63233656A JP2733259B2 (en) 1988-09-20 1988-09-20 Porous microcellulose particles

Publications (2)

Publication Number Publication Date
JPH0284401A JPH0284401A (en) 1990-03-26
JP2733259B2 true JP2733259B2 (en) 1998-03-30

Family

ID=16958466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63233656A Expired - Lifetime JP2733259B2 (en) 1988-09-20 1988-09-20 Porous microcellulose particles

Country Status (1)

Country Link
JP (1) JP2733259B2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW260612B (en) * 1993-01-05 1995-10-21 Asahi Chemical Ind
CN1051093C (en) * 1994-09-16 2000-04-05 中国科学院广州化学研究所 Manufacture of nm avicel powder by solvent process
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
KR100496749B1 (en) 2000-07-05 2005-06-22 아사히 가세이 가부시키가이샤 Cellulose powder
ATE508735T1 (en) 2001-12-19 2011-05-15 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
JP4166562B2 (en) * 2002-12-25 2008-10-15 旭化成株式会社 Cellulosic material with large specific surface area
GB0317752D0 (en) * 2003-07-29 2003-09-03 Univ York Expanded biomaterials for adsorption and separation processes
EP1712583B1 (en) 2004-01-30 2020-09-16 Asahi Kasei Kabushiki Kaisha Porous cellulose aggregate and formed product composition comprising the same
JP2005255619A (en) * 2004-03-11 2005-09-22 Asahi Kasei Chemicals Corp Solid pharmaceutical preparation composition comprising sublimable active ingredient and porous cellulose particle
JP2005255618A (en) * 2004-03-11 2005-09-22 Asahi Kasei Chemicals Corp Solid pharmaceutical preparation composition comprising slightly water-soluble active ingredient and porous cellulose particle
EP1873196B1 (en) 2005-04-22 2016-04-13 Asahi Kasei Chemicals Corporation Porous cellulose aggregate and molding composition thereof
JP4858679B2 (en) * 2005-09-30 2012-01-18 日本ケミコン株式会社 Capacitor separator and capacitor using the same
JP7269239B2 (en) 2018-06-29 2023-05-08 日揮触媒化成株式会社 POROUS CELLULOSE PARTICLES, MANUFACTURING METHOD THEREOF, AND COSMETIC
JP7199871B2 (en) * 2018-08-10 2023-01-06 日揮触媒化成株式会社 POROUS CELLULOSE PARTICLES, MANUFACTURING METHOD THEREOF, AND CLEANING COSMETIC
JP7265331B2 (en) * 2018-09-28 2023-04-26 日揮触媒化成株式会社 Porous cellulose particles and cosmetics
GB201909137D0 (en) * 2019-06-25 2019-08-07 Univ Aston Mesoporous polymeric particulate material
WO2021033742A1 (en) 2019-08-20 2021-02-25 日揮触媒化成株式会社 Particles containing starch, method for producing same, and cosmetic preparation
JP7328268B2 (en) 2021-02-19 2023-08-16 日揮触媒化成株式会社 Coated particles, method for producing the same, and cosmetic

Also Published As

Publication number Publication date
JPH0284401A (en) 1990-03-26

Similar Documents

Publication Publication Date Title
JP2733259B2 (en) Porous microcellulose particles
JP2642486B2 (en) Ultrafine particle method for poorly soluble drugs
Kleinebudde The crystallite-gel-model for microcrystalline cellulose in wet-granulation, extrusion, and spheronization
US5474989A (en) Drug composition
Chatlapalli et al. Physical characterization of HPMC and HEC and investigation of their use as pelletization aids
KR101960244B1 (en) Process for producing cellulose derivatives of high bulk density and good flowability
US4254099A (en) Pharmaceutical tablet composition
JPH04266872A (en) Heterocyclic compound
KR20170016398A (en) Method for the production of granules comprising surface-reacted calcium carbonate
JP2840132B2 (en) Method for producing S (+)-ibuprofen particles
US4438263A (en) Cellulose granules and process for producing the same
JP2869103B2 (en) Low solubility drug supported on polymer base in form suitable for improving dissolution rate and method for producing the same
JP2535054B2 (en) Porous cellulose particles
Prieto et al. Starch–dextrin mixtures as base excipients for extrusion–spheronization pellets
Krueger et al. “MCC SANAQ® burst”—a new type of cellulose and its suitability to prepare fast disintegrating pellets
CA2702055C (en) Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
JP3004758B2 (en) Processed starch with excellent binding and disintegration properties
JP2859919B2 (en) Method for improving dissolution of poorly soluble drugs
JP2000281561A (en) New solid dispersion preparation by solvent method
CN108864069A (en) A kind of razaxaban particle and the preparation method and application thereof
SHIRAISHI et al. Studies on the granulation process of granules for tableting with a high speed mixer. I. Physical properties of granules for tableting
Sonaglio et al. Physical characterization of two types of microcrystalline cellulose and feasibility of microspheres by extrusion/spheronization
JPH01152103A (en) Spherical particle of cellulose derivative and preparation thereof
JPH10502937A (en) Preparation of fusidic acid tablets
WO2017209216A1 (en) Method for producing pharmaceutical composition containing microparticles of sparingly-soluble drug

Legal Events

Date Code Title Description
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081226

Year of fee payment: 11

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081226

Year of fee payment: 11